There’s a lot to be optimistic about in the Healthcare sector as 3 experts just weighed in on bluebird bio
bluebird bio (NASDAQ: BLUE) received a Hold rating and a $69 price target from Morgan Stanley analyst Matthew Harrison today.
Debjit Chattopadhyay of Roth Capital has maintained a Buy rating on bluebird bio Inc (NASDAQ:BLUE) with a price target of
In a report released today, Debjit Chattopadhyay from Roth Capital maintained a Buy rating on bluebird bio (NASDAQ: BLUE). The company’s